JAB1 expression is associated with inverse expression of p27kip1 in hepatocellular carcinoma

Hepato-Gastroenterology

Volumn 57, Issue 99-100, 2010, Pages 547-553

  Qin, Jun ^a   Wang, Zhiwei ^a   Wang, You ^b   Ma, Lilin ^a   Ni, Qichao ^a   Ke, Jing ^a  

^a NANTONG UNIVERSITY   (China)

^b Wuxi Maternal and Child Health Hospital   (China)

Author keywords

As2O 3; HCC; Immunohistochemistry; JAB1; p27kip1; SMMC 7721

Indexed keywords

ARSENIC TRIOXIDE; BINDING PROTEIN; C JUN ACTIVATION DOMAIN BINDING PROTEIN 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; EXPORTIN 1; KI 67 ANTIGEN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL CYCLE; CELL CYCLE ARREST; CELL NUCLEUS; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPLASM; DRUG ACTIVITY; FLOW CYTOMETRY; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; LIVER; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN TRANSPORT; STAINING; WESTERN BLOTTING;

APOPTOSIS; ARSENICALS; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CELL LINE, TUMOR; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KARYOPHERINS; KI-67 ANTIGEN; LIVER NEOPLASMS; OXIDES; PEPTIDE HYDROLASES; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 77955500377     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Aderca I, Moser CD, Veerasamy M, et al: The JNK inhibitor SP600129 enhances apoptosis of HCC cells induced by the tumor suppressor WWOX. J Hepatol 2008; 49: 373-83.
3. Chetty R: p27 Protein and cancers of the gastrointestinal tract and liver: an overview. J Clin Gastroenterol 2003; 37: 23-7.
4. Zhang YJ, Jiang W, Chen CJ, et al: Amplification and overexpression of cyclin D1 in human hepatocellular carcinoma. Biochem Biophys Res Commun 1993; 196: 1010-6.
5. Zhang YJ, Chen SY, Chen CJ, Santella RM: Polymorphisms in cyclin D1 gene and hepatocellular carcinoma. Mol Carcinog 2002; 33: 125-9.
6. Li KK, Ng IO, Fan ST, Albrecht JH, Yamashita K, Poon RY: Activation of cyclin-dependent kinases CDC2 and CDK2 in hepatocellular carcinoma. Liver 2002; 22: 259-68. (Pubitemid 34846365)
7. Kohzato N, Dong Y, Sui L, et al: Overexpression of cyclin E and cyclin-dependent kinase 2 is correlated with development of hepatocellular carcinomas. Hepatol Res 2001; 21: 27-39. (Pubitemid 32725373)
8. Kita Y, Masaki T, Funakoshi F, et al: Expression of G1 phase-related cell cycle molecules in naturally developing hepatocellular carcinoma of Long-Evans Cinnamon rats. Int J Oncol 2004; 24: 1205-11.
9. Coats S, Flanagan WM, Nourse J, Roberts JM: Requirement of p27Kip1 for restriction point control of the fibroblast cell cycle. Science 1996; 272: 877-80. (Pubitemid 26154591)
10. Toyoshima H, Hunter T: p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 1994; 78: 67-74.
11. Sherr CJ, Roberts JM: Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 1995; 9: 1149-63.
12. Sherr CJ, Roberts JM: CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999; 13: 1501-12.
13. Zhou Q, He Q, Liang LJ: Expression of p27, cyclin E and cyclin A in hepatocellular carcinoma and its clinical significance. World J Gastroenterol 2003; 9: 2450-4. (Pubitemid 37461246)
14. Ito Y, Matsuura N, Sakon M, et al: Expression and prognostic roles of the G1-S modulators in hepatocellular carcinoma: p27 independently predicts the recurrence. Hepatology 1999; 30: 90-9. (Pubitemid 29300574)
15. Fiorentino M, Altimari A, D'Errico A, et al: Acquired expression of p27 is a favorable prognostic indicator in patients with hepatocellular carcinoma. Clin Cancer Res 2000; 6: 3966-72.
16. Qin LF, Ng IO: Expression of p27(KIP1) and p21(WAF1/CIP1) in primary hepatocellular carcinoma: clinicopathologic correlation and survival analysis. Hum Pathol 2001; 32: 778-84.
17. Claudio PP, Russo G, Kumar CA, et al: pRb2/p130, vascular endothelial growth factor, p27(KIP1), and proliferating cell nuclear antigen expression in hepatocellular carcinoma: their clinical significance. Clin Cancer Res 2004; 10: 3509-17.
18. Claret FX, Hibi M, Dhut S, Toda T, Karin M: A new group of conserved coactivators that increase the specificity of AP-1 transcription factors. Nature 1996; 383: 453-7. (Pubitemid 26330837)
19. Tomoda K, Yoneda-Kato N, Fukumoto A, Yamanaka S, Kato JY: Multiple functions of Jab1 are required for early embryonic development and growth potential in mice. J Biol Chem 2004; 279: 43013-8. (Pubitemid 39372195)
20. Ahn J, Hong SA, Lee SE, et al: Cytoplasmic localization of Jab1 and p27 Kip1 might be associated with invasiveness of papillary thyroid carcinoma. Endocr J 2009; 56: 707-13.
21. Tomoda K, Kubota Y, Kato J: Degradation of the cyclin-dependent-kinase inhibitor p27Kip1 is instigated by Jab1. Nature 1999; 398: 160-5. (Pubitemid 29135455)
22. Carrano AC, Eytan E, Hershko A, Pagano M: SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol 1999; 1: 193-9. (Pubitemid 129500937)
23. Ivan D, Diwan AH, Esteva FJ, Prieto VG: Expression of cell cycle inhibitor p27Kip1 and its inactivator Jab1 in melanocytic lesions. Mod Pathol 2004; 17: 811-8. (Pubitemid 38843364)
24. Rassidakis GZ, Claret FX, Lai R, et al: Expression of p27(Kip1) and c-Jun activation binding protein 1 are inversely correlated in systemic anaplastic large cell lymphoma. Clin Cancer Res 2003; 9: 1121-8. (Pubitemid 36323721)
25. Esteva FJ, Sahin AA, Rassidakis GZ, et al: Jun activation domain binding protein 1 expression is associated with low p27(Kip1)levels in node-negative breast cancer. Clin Cancer Res 2003; 9: 5652-9.
26. Ito Y, Yoshida H, Nakamura Y, et al: Expression of Jun activation domain-binding protein 1 and p27 (Kip1) in thyroid medullary carcinoma. Pathology 2005; 37: 216-9.
27. Goto A, Niki T, Moriyama S, et al: Immunohistochemical study of Skp2 and Jab1, two key molecules in the degradation of P27, in lung adenocarcinoma. Pathol Int 2004; 54: 675-81. (Pubitemid 39297292)
28. Sui L, Dong Y, Ohno M, et al: Jab1 expression is associated with inverse expression of p27(kip1) and poor prognosis in epithelial ovarian tumors. Clin Cancer Res 2001; 7: 4130-5. (Pubitemid 34044637)
29. Patil MA, Gutgemann I, Zhang J, et al: Array-based comparative genomic hybridization reveals recurrent chromosomal aberrations and Jab1 as a potential target for 8q gain in hepatocellular carcinoma. Carcinogenesis 2005; 26: 2050-7.
30. Berg JP, Zhou Q, Breuhahn K, et al: Inverse expression of Jun activation domain binding protein 1 and cell cycle inhibitor p27Kip1: influence on proliferation in hepatocellular carcinoma. Hum Pathol 2007; 38: 1621-7.
31. Kojiro M: Pathological evolution of early hepatocellular carcinoma. Oncology 2002; 62 Suppl 1: 43-7.
32. Liu B, Pan S, Dong X, et al: Opposing effects of arsenic trioxide on hepatocellular carcinomas in mice. Cancer Sci 2006; 97: 675-81.
33. Han YH, Kim SZ, Kim SH, Park WH: Arsenic trioxide inhibits the growth of Calu-6 cells via inducing a G2 arrest of the cell cycle and apoptosis accompanied with the depletion of GSH. Cancer Lett 2008; 270: 40-55.
34. Huang YT, Iwamoto K, Kurosaki T, Nasu M, Ueda S: The neuronal POU transcription factor Brn-2 interacts with Jab1, a gene involved in the onset of neurodegenerative diseases. Neurosci Lett 2005; 382: 175-8.
35. Tomoda K, Kubota Y, Arata Y, et al: The cytoplasmic shuttling and subsequent degradation of p27Kip1 mediated by Jab1/CSN5 and the COP9 signalosome complex. J Biol Chem 2002; 277: 2302-10.
36. Kouvaraki MA, Rassidakis GZ, Tian L, Kumar R, Kittas C, Claret FX: Jun activation domain-binding protein 1 expression in breast cancer inversely correlates with the cell cycle inhibitor p27(Kip1). Cancer Res 2003; 63: 2977-81.
37. Ito Y, Yoshida H, Matsuzuka F, et al: Jun activation domain-binding protein 1 expression in malignant lymphoma of the thyroid: its linkage to degree of malignancy and p27 expression. Anticancer Res 2003; 23: 4121-5.
38. Dong Y, Sui L, Watanabe Y, Yamaguchi F, Hatano N, Tokuda M: Prognostic significance of Jab1 expression in laryngeal squamous cell carcinomas. Clin Cancer Res 2005; 11: 259-66.
39. Sun BH, Zhang J, Wang BJ, et al: Analysis of in vivo patterns of caspase 3 gene expression in primary hepatocellular carcinoma and its relationship to p21 (WAF1) expression and hepatic apoptosis. World J Gastroenterol 2000; 6: 356-60.
40. Liu L, Qin S, Chen H, Wang J, Ma J, Liu W: [An experimental study on arsenic trioxide-selectively induced human hepatocarcinoma cell lines apoptosis and its related genes]. Zhonghua Gan Zang Bing Za Zhi 2000; 8: 367-9.
41. Filipits M, Puhalla H, Wrba F: Low p27Kip1 expression is an independent prognostic factor in gallbladder carcinoma. Anticancer Res 2003; 23: 675-9.
42. Deshpande A, Sicinski P, Hinds PW: Cyclins and cdks in development and cancer: a perspective. Oncogene 2005; 24: 2909-15.